首页> 美国卫生研究院文献>Oncotarget >Long noncoding RNA CCAT2 as a novel biomaker of metastasis and prognosis in human cancer: a meta-analysis
【2h】

Long noncoding RNA CCAT2 as a novel biomaker of metastasis and prognosis in human cancer: a meta-analysis

机译:长非编码RNA CCAT2作为人类癌症转移和预后的新型生物制造者:一项荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Colon cancer-associated transcript2 (CCAT2), a long noncoding RNA (LncRNA), has been found to function as an oncogene in various cancers. However, the clinical value of CCAT2 in cancers remains unclear. Therefore, we performed this meta-analysis to investigate the association between CCAT2 level and metastasis & prognosis in malignant tumors. The meta analysis was performed by using a systematic search in PubMed, Web of Science, and Cochrane Library from inception to NOV 17, 2016. According to the inclusion and exclusion criteria,9 studies with 1084 patients were included in the meta-analysis.The result showed that overexpression of CCAT2 is positively correlated with lymph node metastasis (Odds ratio,OR=3.57, 95 % confidence interval(CI): 1.79-7.13, p<0.001) in a random-effects model (I2=71%, p=0.008) and distant metastasis(OR=7.68, 95 % CI: 3. 29-17.96, p<0.001) in a random-effects model (I2=41.9%, p=0.16).Likewise,we also found that high CCAT2 expression could predict unfavourable overall survival with pooled hazard ratio (HR) of 2.23 (95 % CI 1.68-2.96, p<0.00001) by a random-effects model (I2=37.5%, p=0.143) and poor metastasis-free survival in cancer patients (HR= 2.08, 95%CI:1.37-3.18 p=0.001) by a fixed-effects model (I2=0.0%, p=0.807). In conclusion,CCAT2 might be served as a novel molecular marker for predicting metastasis and prognosis in various human-cancers.
机译:结肠癌相关的转录物2(CCAT2),一种长的非编码RNA(LncRNA),已发现在多种癌症中起癌基因的作用。但是,CCAT2在癌症中的临床价值仍不清楚。因此,我们进行了这项荟萃分析,以研究CCAT2水平与恶性肿瘤转移和预后之间的关系。从开始到2016年11月17日,通过在PubMed,Web of Science和Cochrane图书馆中进行系统搜索进行荟萃分析。根据纳入和排除标准,荟萃分析包括9项研究,涉及1084例患者。结果表明,在随机效应模型中,CCAT2的过表达与淋巴结转移呈正相关(几率,OR = 3.57,95%置信区间(CI):1.79-7.13,p <0.001)(I 2 < /sup>=71%,p=0.008)和远处转移(OR = 7.68,95%CI:3。29-17.96,p <0.001)(I 2 = 41.9%,p = 0.16)。同样,我们还发现,高CCAT2表达可以预测不良总生存,随机效应模型的总危险比(HR)为2.23(95%CI 1.68-2.96,p <0.00001)(通过固定效应模型(I),I 2 = 37.5%,p = 0.143)和癌症患者的无转移生存不良(HR = 2.08,95%CI:1.37-3.18 p = 0.001) 2 = 0.0%,p = 0.807)。总之,CCAT2可以作为预测各种人类癌症转移和预后的新型分子标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号